Global Adrenocortical Carcinoma Drugs Market 2019-2023
SKU ID : TNV-14498979 | Publishing Date : 23-Jul-2019 | No. of pages : 114
Detailed TOC of Global Adrenocortical Carcinoma Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Chemotherapy - Market size and forecast 2018-2023
Targeted therapy - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increasing R&D for adrenocortical carcinoma
Advances in imaging techniques for adrenal tumors
Emergence of new diagnostic methods
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Laboratoire HRA Pharma SAS
Progenics Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Drugs under development
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 46: Bristol-Myers Squibb Co. - Business segments
Exhibit 47: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 48: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 49: Bristol-Myers Squibb Co. - Key offerings
Exhibit 50: Eli Lilly and Co. - Vendor overview
Exhibit 51: Eli Lilly and Co. - Business segments
Exhibit 52: Eli Lilly and Co. - Organizational developments
Exhibit 53: Eli Lilly and Co. - Geographic focus
Exhibit 54: Eli Lilly and Co. - Segment focus
Exhibit 55: Eli Lilly and Co. - Key offerings
Exhibit 56: Laboratoire HRA Pharma SAS - Vendor overview
Exhibit 57: Laboratoire HRA Pharma SAS - Key offerings
Exhibit 58: Progenics Pharmaceuticals Inc. - Vendor overview
Exhibit 59: Progenics Pharmaceuticals Inc. - Business segments
Exhibit 60: Progenics Pharmaceuticals Inc. - Organizational developments
Exhibit 61: Progenics Pharmaceuticals Inc. - Key offerings
Exhibit 62: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 63: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 64: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 65: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 66: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 67: Validation techniques employed for market sizing
Exhibit 68: Definition of market positioning of vendors